{"entity":{"id":"nct02213926","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Acalabrutinib in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.","summary":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT02213926 by Acerta Pharma BV, with 124 participants enrolled, started 2015-03-02 and due to reach its primary completion in 2020-12-04. Interventions recorded: ACP-196 (acalabrutinib). Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02213926","url":"https://clinicaltrials.gov/study/NCT02213926"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["acalabrutinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02213926","phase":"2","setting":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma","sponsor":"Acerta Pharma BV","enrolled":124,"outcomes":[]},"route":"/trials/nct02213926/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}